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Summary Incidence data on a population-based series of bone, soft tissue and visceral sarcomas from the
North West of England are presented. The data are derived mainly from a total of 429 cases registered with
the North Western Regional Cancer Registry and diagnosed during the period 1982-84, 76% of which were
confirmed as sarcomas by a panel of five pathologists. Overall incidence of confirmed sarcomas per million
person years was slightly higher in females (26.81) than in males (24.71) but there was no sex difference when
38 non-reviewed cases were taken into consideration (females 29.07, males 28.83). After exclusion of tumours
of female genital tract, incidence of soft tissue tumours was very similar in both sexes (females 18.25, males
18.70). Bone tumours were almost twice as frequent in males (6.01) as in females (3.55).
Studies of the incidence of sarcomas have been hampered by
the use of the classification system ICD (WHO, 1978) in
most published statistics. ICD records solid tumours mainly
by site and does not distinguish between different histological
types of tumours, e.g. carcinomas or sarcomas of visceral
sites, or between different histological sub-types of sarcoma.
Most studies of the aetiology of sarcomas have concent-
rated upon environmental agents such as irradiation, viruses
and chemical agents, particularly exposure to chlorophenoxy
herbicides (IARC, 1987). Host factors including precursor
lesions, inherited cancer predisposition syndromes and
immunosuppression have also been implicated as causative
agents (Fraumeni & Boice, 1982; Tucker & Fraumeni, 1982).
Accurate recognition of histological sub-type of sarcoma is a
prerequisite for the study of such aetiological factors as it is
possible that different sub-types may be related to different
causative agents. The data reported in this paper relate to a
unique series of peer-reviewed sarcomas ascertained from a
defined population. They provide incidence figures by histo-
logical type, sex and age for the period 1982-84 which may
be of use in studies of aetiology, and form a base-line for
planning of services for the clinical management of these rare
cancers.
Methods
Diagnoses eligible for the study were those malignant soft
tissue sarcomas given in the modified WHO scheme listed by
Enzinger and Weiss (1988), including sarcomas arising in the
gastrointestinal tract and in the female genital tract, together
with osteosarcoma, chondrosarcoma, Ewing's tumour and
other primary sarcomas of bone. Mesothelioma and certain
mixed neoplasms e.g. carcinosarcoma and Miillerian mixed
tumour were excluded but a small number of other tumours
for which the diagnosis of sarcoma was considered a possi-
bility or where degree of malignancy is uncertain were
included in the review.
The North Western Regional Cancer Registry (NWRCR)
provided lists of all cases with eligible diagnoses and anni-
versary date between January 1 1982 and December 31 1984.
In addition, all cancer registrations with anniversary years
1982-84 were scrutinized individually to identify cases not
registered as sarcomas, but where sarcoma was mentioned
either in a histology report or as a cause of death.
Ascertainment for the NWRCR is via registrations
submitted by peripatetic clerks, hospitals and general practi-
tioners, and from death notifications supplied by the Office of
Population Censuses and Surveys (North Western Regional
Health Authority, 1990). Instead of date of diagnosis, the
registry records anniversary date, which is the date of first
treatment if treated, date first admitted to hospital if never
treated, date first seen for the condition if neither admitted
nor treated or, if registered from a death notification alone,
the date of death. For the vast majority of cases the anniver-
sary date and diagnosis date will fall within the same calen-
dar year. The only exceptions are a small number of cases
diagnosed at the beginning or end of a year. For the pur-
poses of this study cases with anniversary dates in 1982-84
have been taken as diagnosed in these years, and it has been
assumed that there is equilibrium between cases diagnosed
during 1982-1984 with anniversary dates outside this period,
and cases diagnosed before 1982 and after 1984 with anniver-
sary date between 1982-84. A final listing of cases was
obtained for cross-checking at the end of 1988 when registra-
tion was considered to be complete for anniversary years
1982-84.
Unstained sections or representative blocks were requested
for each case. Sections were stained with haematoxylin and
eosin and circulated to each of the five panel pathologists
together with a brief clinical summary of the case. Members
recorded their individual diagnoses without discussion and
their reports were circulated. The final (panel) diagnosis was
arrived at by consensus after discussion at meetings where
slides were available and, if necessary, after the application of
special stains including immunohistochemistry. A detailed
description of the review method is given elsewhere (Harris et
al., 1991). Final diagnoses were coded using ICD-O (WHO,
1976) with the creation of sub-categories for variants of
certain tumours e.g. malignant fibrous histiocytoma, liposar-
coma and chondrosarcoma. Neurofibrosarcoma and malig-
nant Schwannoma were coded to 95403 and all tumours of
this type were described as malignant peripheral nerve sheath
tumours.
This study ofincidence is based upon those cases for which
a final (panel) diagnosis of sarcoma was agreed. Additional
incidence figures have also been calculated to take account of
cases originally registered as a result of clinical diagnosis
and those where material could not be obtained or a diag-
nosis could not be made because of technical difficulties. On
further investigation certain cases were found to have more
than one cancer registration for the same diagnosis; these
were included once only in the incidence calculations or were
excluded if at the time of the earliest anniversary date the
case was resident outside the North Western Region or if this
date was prior to January 1 1982.
Annual incidence rates per million population were
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calculated by dividing the total number of cases by the sum
of the mid-year population estimates for those resident in the
North West Health Authority Region at that time. Median
age at diagnosis for all cases, by sex, by site and for certain
histological groups was calculated.
Results
A total of 468 cases (92 bone tumours; 376 soft tissue
tumours, including 110 of visceral origin) were originally
ascertained for the study. Of the 450 cases originally regis-
tered as sarcomas 313 were confirmed as such by the panel.
An additional two cases out of a total of 18 selected because
of uncertain malignancy or because of the possibility of
diagnosis of sarcoma, were also diagnosed as sarcomas. Fur-
ther scrutiny of the 315 reviewed cases with a final diagnosis
of sarcoma resulted in five cases being excluded from these
incidence calculations: four had dual cancer registration and
were originally diagnosed outside the North West Regional
Health Authority (NWRHA) area; one case had anniversary
date incorrectly notified. The remaining 310 cases with a final
confirmed diagnosis of sarcoma are shown in Table I and
include two cases diagnosed late in 1981 but with anniversary
date in 1982.
In addition to the 310 histologically confirmed cases,
certain other cases were taken into consideration for calcula-
tion of incidence rates. During the period 1982-84 19 cases
had been diagnosed on the basis of clinical criteria only; 13
cases had an original histological diagnosis of sarcoma but
no material was received or could be obtained from the
blocks sent; and in a further six cases material was received
but no diagnosis made. The original registered diagnoses for
these 38 cases are shown in Table II.
Table III shows incidence rates per million person years
for all reviewed cases combined, all soft tissue sarcomas
(sub-divided by site), all bone sarcomas, and for the different
histological sub-types represented in the study population.
Rates given in parentheses represent the higher values based
upon reviewed cases together with all the clinically-diagnosed
cases and all cases for whom material was not obtained or a
diagnosis could not be made. Although about three-quarters
of the non-reviewed cases are likely to be sarcomas, because
of the uncertainty in diagnosis (Harris et al., 1991) most of
the following comments relate to reviewed cases only, except
where stated.
Incidence of bone and soft tissue sarcomas overall (includ-
ing visceral sarcomas) was slightly higher in females than in
males but there was no sex difference when non-reviewed
cases were taken into account. Incidence of non-visceral
tumours was similar in both sexes, but visceral tumours were
more common in females, the difference being accounted for
mainly by tumours of female genital tract. Bone sarcomas
were almost twice as frequent in males as in females.
Distribution by 5-year age band for all cases is shown in
Figure 1. Incidence, in general, increased with increasing age
to a peak in the 70-74 year age group. Median age at
diagnosis (reviewed cases only) was 61 years for males, 57
years for females and 59.5 years overall. Age distribution for
males and females were very similar but with a more sharply-
defined and higher peak in incidence for men starting at age
50 years and reaching a maximum at age 70-74 years. In
women incidence started to rise steadily from the age of 30
years and continued to a maximum at age 80-84 years.
Much of this increased incidence in the middle years from
35-70 is accounted for by the occurrence of tumours found
exclusively in women, with 18 out of 20 leiomyosarcomas of
the female genital tract and eight out of nine endometrial
stromal sarcomas being diagnosed in this age range. In addi-
tion to the highest levels of incidence seen in old age there
were smaller peaks apparent in both males and females in
very young children and in the years covering adolescence
and young adulthood. Seven tumours were seen in children
aged 0-4 years: three embryonal rhabdomyosarcomas, one
embryonal sarcoma, two spindle cell sarcomas and one fibro-
Table I Cases confirmed as sarcomas diagnosed 1982-84
Histology Male Female Total
Soft tissue sarcomas
Leiomyosarcoma
Gastrointestinal tract
Female genital tract
Soft tissue and miscellaneous sites
Malignant fibrous histiocytoma
NOS
Storiform-pleomorphic
Myxoid
Giant cell
Mixed pattern
Sarcoma NOS
Gastrointestinal tract
Female genital tract
Soft tissue and miscellaneous sites
Liposarcoma
NOS
Well differentiated
Myxoid
Round cell
Pleomorphic
Fibroblastic
De-differentiated
Malignant peripheral nerve sheath
tumour
Rhabdomyosarcoma
Alveolar
Embryonal
Female genital tract
Soft tissue and miscellaneous
sites
Pleomorphic
Haemangiosarcoma
Endometrial stromal sarcoma
Synovial sarcoma
Dermatofibrosarcoma protuberans
Fibrosarcoma
Extra-skeletal osteosarcoma
Extra-skeletal chondrosarcoma
Malignant haemangiopericytoma
Extra-skeletal myxoid
chondrosarcoma
Extra-skeletal Ewing's tumour
Alveolar soft part sarcoma
Malignant rhabdoid tumour of soft
tissue
Malignant mesenchymoma
Embryonal sarcoma
Clear cell sarcoma
Kaposi's sarcoma
Total soft tissue sarcoma
Total gastrointestinal tract
Total female genital tract
Total soft tissue and miscellaneous
sites
Total visceral sarcomas
Bone tumours
Osteosarcoma
Chondrosarcoma
Ewing's tumour
Malignant fibrous histiocytoma
Haemangiosarcoma
Chordoma
Sarcoma NOS
Total Bone tumours
Total Sarcomas
5
1
3
1
1
0
0
7
5
20
23
5
13
3
3
0
0
1
12
2
4
4
2
0
1
5
3 2
1
2 1
2 0
6 4
9
0 5
2 3
1 3
3 1
1 3
1 2
1 1
I
0
0
1
109
10
99
19
14
15
3
l
0
35
144
01
1
0
144
5
31
108
39
10
7
4
0
0
0
1
22
166
14
20
37a
job
25
9
4
1
1
1
32c
3
5
7
3
1
1
1
12b
5
1
3d
2
loe
9
5
5
4
4
4
3
2
2
2
1
1
15
1
31
207
58
24
22
7
1
1
57
310
aIncludes oneeach ofkidney, bladder, palate and lung;bIncludes one
lung; cIncludes one each oftrachea, lung, liver and pancreas; dIncludes
one soft palate; 'Includes one liver.
sarcoma. In the age range 10-24 years, five of the 36
tumours seen were also rhabdomyosarcomas (one embryonal,
and four alveolar) but the peak at this age was almost
entirely accounted for by bone tumours: 14 osteosarcomas,
one chondrosarcoma and five Ewing's tumours.
Separate distributions for soft tissue sarcomas (excluding
those of female genital tract) and bone sarcomas are shownINCIDENCE OF SARCOMAS 1147
Table II Other cases included for incidence calculations 1982-1984
Male Female Total
Clinical diagnosis
Soft tissue tumours
Sarcoma NOS 5 3 8a
Bone tumours
Osteosarcoma 8 1 9
Sarcoma NOS 0 1 1
Chordoma 0 1 1
No material received
Soft tissue tumours
Leiomyosarcoma 0 1 la
Sarcoma NOS 2 1 3b
Liposarcoma 1 0 1
Synovial sarcoma 0 2 2
Kaposi's sarcoma 1 0 1
Bone tumours
Osteosarcoma 1 1 2
Chondrosarcoma 1 0 1
Chordoma 1 0 1
Sarcoma NOS 1 0 1
No diagnosis made
Soft tissue tumours
Leiomyosarcoma 0 1 la
Liposarcoma 2 0 2
Haemangiosarcoma 1 0 1
Bone tumours
Osteosarcoma 0 1 1
Chondrosarcoma 0 1 1
Overall Total 24 14 38
aIncludes one uterus; bIncludes one lung.
in Figures 2 and 3. While the pattern for soft tissue tumours
is very similar to the overall distribution for all cases, the
distribution for bone tumours is strikingly bi-modal with
peaks at ages 10-19 years and at 70-79 years. The majority
of tumours seen in the adolescent group were, in fact, bone
tumours (18 out of 26) and included 12 osteosarcomas, one
chondrosarcoma and five Ewing's tumours. In the older age
peak chondrosarcoma (six cases) was represented more fre-
quently than osteosarcoma (four cases). Because of the
difference in age distribution of bone and soft tissue tumours,
median age at diagnosis was markedly different in the two
groups. Median age at diagnosis for soft tissue tumours
(excluding those of female genital tract) was 62 years in both
males and females; and for bone tumours was 33 years
overall, 33 years in males and 32.5 years in females. Median
age at diagnosis for sarcomas of female genital tract was 54
years.
The two most commonly diagnosed soft tissue tumours in
the reviewed series were leiomyosarcoma and malignant
fibrous histiocytoma (MFH) and age distributions for these
are represented in Figures 4 and 5. No cases of leiomyosar-
coma were seen below age 30 years and the distributions for
males and females were similar except for the greater inci-
dence in middle-aged females accounted for mainly by
uterine tumours as mentioned previously. Leiomyosarcoma
of gastrointestinal tract did not occur below age 50 years in
males or females and reached its highest incidence at 70-74
years in men and 80-84 years in women. Leiomyosarcoma of
soft tissue and other sites was occasionally seen under age 50
years (four cases out of 37) but this again was predominantly
a disease of older age groups. Median age for all leiomyosar-
coma was 65 years in males and females; for female genital
tract 56 years; for gastrointestinal tract 69 years overall, 67
years in males and 72 years in females; and for soft tissue
and other sites 68 years overall, 63.5 years in males and 70
years in females.
Only two cases of MFH were seen under the age of 45
years, one in a 6 year old girl and another in a 16 year old
boy. Hence this sub-type of sarcoma also appears to be
predominantly seen in old age reaching a maximum incidence
in the 75-79 age group in men and 85 + age group in
women. Median age at diagnosis was 69 years in males, 72.5
years in females and 70.5 years overall.
Table I1I Incidence rates for histologically-confirmed sarcomas
Histological type
Soft tissue tumours
Leiomyosarcoma
Gastrointestinal tract
Female genital tract
Soft tissue and misc.
sites
Malignant fibrous
histiocytoma
Sarcoma NOS
Gastrointestinal tract
Female genital tract
Soft tissue and misc.
sites
Liposarcoma
Malignant peripheral nerve
sheath tumour
Rhabdomyosarcoma
Female genital tract
Soft tissue and misc.
sites
Haemangiosarcoma
Endometrial stromal
sarcoma
Synovial sarcoma
Dermatofibrosarcoma
protuberans
Fibrosarcoma
Extra-skeletal
osteosarcoma
Extra-skeletal
chondrosarcoma
Malignant haemangio-
pericytoma
Extra-skeletal myxoid
chondrosarcoma
Extra-skeletal Ewing's
tumour
Alveolar soft part sarcoma
Malignant rhabdoid
tumour of soft tissue
Malignant mesenchymoma
Embryonal sarcoma
Clear cell sarcoma
Kaposi's sarcoma
Total soft tissue sarcoma I
Gastrointestinal tract
Female genital tract
Soft tissue and misc. I
sites
Total visceral sarcomas
Bone twuours
Osteosarcoma
Chondrosarcoma
Ewing's tumour
Malignant fibrous
histiocytoma
Haemangiosarcoma
Chordoma
Sarcoma NOS
Total bone tumours
Total sarcomas i
1982-84
Rate per 106 person years
Male Female Overall
3.95 7.75 (8.07)'
1.54 0.81
_ 3.23 (3.55)
2.40 3.71
4.29 3.88
3.60 (4.80) 2.10 (2.75)
0.17 b
- 0.16 (0.32)
3.43 (4.63) 1.94 (2.42)
1.20 (1.72)
1.20
1.20
1.20
1.03 (1.20)
b
0.34
0.17
0.51
0.17
0.17
0.17
0.17
0.17
b
0.17
b
b
0.17 (0.34)
2.26
0.81
0.65
0.16
0.48
0.65
1.45
0.81 (1.13)
0.48
0.48
0.16
0.48
0.32
0.16
0.16
0.16
0.16
b
0.16
0.16
b
I .~~~~~~~~~~591(.7
5.91 (6.07)
1.16
3.08
4.08
2.83 (3.74)
0.08
2.66 (3.49)
1.75 (2.00)
1.00
0.92
0.83
0.83 (0.92)
0.42 (0.58)
0.42
0.33
0.33
0.33
0.25
0.17
0.17
0.17
0.08
0.08
0.08
0.08
0.08 (0.17)
18.70 (20.76) 23.26 (24.55) 21.05 (22.71)
1.72 0.81 1.25
5.01 (5.49) -
16.99 (19.05) 17.44 (18.25) 17.22 (18.64)
3.26 (3.44) 6.30 (6.78) 4.83 (5.16)
2.40 (3.95)
2.57 (2.75)
0.51
0.17
0.17
0.17 (0.34)
b (0.17)
6.01 (8.07)
24.71 (28.83)
1.61 (2.10)
1.13 (1.29)
0.65
b
b
b (0.16)
0.16 (0.32)
3.55 (4.52)
26.81 (29.07)
2.00 (3.00)
1.83 (2.00)
0.58
0.08
0.08
0.08 (0.25)
0.08 (0.25)
4.74 (6.24)
25.79 (28.95)
aMaximum incidence rate including non reviewed cases; bNo cases
observed in this period.
Age distributions for the two commonest bone tumours,
osteosarcoma and chondrosarcoma are shown in Figures 6
and 7. From these it can be seen that the bi-modal distribu-
tion in incidence of bone tumours described earlier was
accounted for by the pattern in diagnosis of osteosarcoma
which peaked in the 15-19 age group and again in old age.
Incidence of chondrosarcoma was almost constant over the
age range 5-59 years except for a small increase at age
35-39 years, but started to rise at 60 years peaking in the
70-74 year age group. Both osteosarcoma and chondrosar-1148 A.L. HARTLEY et al.
coma were more common in males than in females and this
difference was particularly striking for osteosarcoma in males
aged 60 years and over. Median age at diagnosis for reviewed
cases with a final diagnosis of osteosarcoma was 18 years
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(males 20 years, females 17 years) and for chondrosarcoma
was 63 years in both sexes. Because, however, the diagnosis
of osteosarcoma was made on clinical grounds only in nine
out of the 40 cases included in the study, the inclusion of
these latter cases, seven ofwhich occurred in individuals over
65 years of age, results in a much higher median age at
diagnosis in osteosarcoma overall i.e. 29 years (males 32
years, females 17 years).
Liposarcoma was not seen under 33 years and was more
common in females than in males up to age 60 years. Median
age at diagnosis was 59 years. Median age at diagnosis for
the 12 cases of malignant peripheral nerve sheath tumour
was 46.5 years. Two of these latter individuals were stated to
have neurofibromatosis and there were indications from the
cancer registration forms and pathology reports that a fur-
ther 2 cases may have been similarly affected.
Rhabdomyosarcoma, specifically the embryonal and alveo-
lar variants, occurred mainly in chidren and young adults.
The two cases of pleomorphic sub-type were diagnosed in
men aged 62 and 72 years. Distribution of Ewing's tumour
paralleled that of osteosarcoma in young people in that seven
of the nine cases occurred in individuals aged 10-25 years.
Two further cases were seen at ages 43 and 46 years.
In 35 cases, although material was reviewed, no specific
type of sarcoma could be specified. These cases were spread
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chondrosarcoma of
over the entire age range and median age at diagnosis was 60
years. In a further nine cases, mainly in the elderly, the
diagnosis of sarcoma NOS was based on clinical criteria
only.
Discussion
Overall annual incidence of sarcomas in this study was about
29 per million with an almost equal incidence in males and
females. While overall incidence appears very similar to that
given for bone and soft tissue tumours in North West Eng-
land (Muir et al., 1987) it must be borne in mind that the
latter figures include tumours of bone and soft tissue other
than sarcomas, and that the current series included sarcomas
of sites e.g. skin, genital tract, gastrointestinal tract, peri-
toneum and retroperitoneum, breast, lung, etc., which, if
classified on a topographical basis as in ICD would be
indistinguishable from carcinomas or other tumours of those
sites. It must also be noted that as a result of the special
histopathological peer review undertaken, approximately
24% of the total reviewed sample had been reclassified as
malignant tumours other than sarcomas or as benign,
borderline or non-neoplastic conditions (Harris et al., 1991).
Reclassification of sarcomas in this manner appears to be a
common feature of other reviewed series (Presant et al., 1986;
Alvegard & Berg, 1989).
No direct comparisons of these incidence figures with other
series are possible as no other centralised peer review of a
complete population-based series of sarcomas has been pub-
lished. Reliable data on childhood sarcomas, however, has
been accrued by the Manchester Children's Tumour Registry
for more than 30 years (Parkin et al., 1988; Birch et al., 1990)
and similar data are now becoming available for other
regions (Craft et al., 1987). Data relating to childhood
sarcomas in the North West are likely to be more accurate
and complete than those for adult patients. Childhood
sarcomas are ascertained directly from histopathologists,
paediatricians, surgeons, radiotherapists and haematologists,
and cross-checked with regional cancer registrations and with
death certificates. Histopathology is subsequently centrally
reviewed. Ascertainment of adult cancers, as described
previously, is improved by the use of peripatetic clerks who
obtain information direct from hospital departments, but
some patients are treated in private hospitals some of which
do not register cases, and information is also more difficult to
obtain on individuals who are treated as outpatients. There is
no centralised pathology review.
The two main prerequisites for the production of reliable
incidence data on sarcomas are that there should be complete
ascertainment of cases derived from a clearly-defined geo-
graphical area with a known population, and that centralised
histopathology review by experienced pathologists should
take place. Since material was obtained and reviewed for
96% of the registered cases entered in the study for whom
previous histopathological diagnosis had been recorded, the
second requirement was felt to have been adequately fulfilled
by the study. Ascertainment of sarcomas in adult patients,
however, was entirely dependent on the efficacy of the regional
cancer registry. Completeness of cancer registration in the
North Western Region was assessed in 1981/1982 at 95% for
cases with anniversary year 1974-77, although completeness
varied by site of cancer and source of data (Nwene & Smith,
1982). No assessment of registration of sarcomas has ever
been made but in view of the quite high mortality of patients
with these tumours there is no reason to assume a registra-
tion level below this figure.
The accuracy of the incidence data, however, are subject to
two potential drawbacks in that the time period of 3 years
which was studied was very short in terms of registration of
rare tumours, and that the starting point for the study was
those cases specifically registered as sarcomas with the
regional registry or where sarcoma was mentioned as a possi-
ble diagnosis on the registration form.
Some histological sub-types of sarcomas are so rarely
encountered that none would be seen during the 3-year
period. Hence no incidence figures can be estimated. Other
rare variants which do happen by chance to have been
diagnosed in the study period may have been given an
incidence figure which was higher than the true frequency of
the tumour. Another possible effect of this rarity of sub-type
would be to underestimate the age range over which the
tumour occurred, and indeed information from the childhood
data referred to previously confirms that some of the rare
sub-types do occur in children under 15 years of age.
A total of 59,784 tumours was registered with the North
Western Regional Cancer Registry during the 3 years of the
study, the vast majority of which were carcinomas. No esti-
mate of the number of these which were mis-diagnosed can
be made and it is, of course, possible that a certain propor-
tion could have been sarcomas and these cases would have
compensated for those which were diagnosed as non-
sarcomas in this study. However, a peer review of 3,000
consecutive surgical pathology cases reported by Whitehead
et al. (1984) resulted in changes regarded as significant in
only 29 (0.96%) cases. None of these were finally diagnosed
as sarcomas so it seems unlikely that any significant changes
to the incidence figures reported here would be made as a
result of central review of all specimens.
Data on bone sarcomas is probably less accurate than that
on soft tissue sarcomas as the bone tumours formed only
22% (75/348) of the total sample and of these almost 24%
t1150 A.L. HARTLEY et al.
(18/75) could not be reviewed, the majority of these because
diagnosis was based upon clinical criteria only. Nevertheless
the overall age-specific incidence rates for the three common-
est bone tumours, osteosarcoma, chondrosarcoma and Ewing's
tumour are essentially similar to those reported by the Third
National Cancer Survey which did specify sub-type and
covered about 10% of the population of the United States
for the years 1969-71 (Cutler & Young, 1975; Fraumeni &
Boice, 1982).
Taking into consideration all the factors relating to ascer-
tainment and their effects on estimates ofincidence rates, it is
felt that the rates presented in this paper are a reasonably
accurate representation of the frequency of occurrence of at
least the commoner types of sarcomas seen in the North
West Region over the period 1982-84. Comparisons with
other series must, however, be made with caution because of
changes in diagnostic nomenclature which may occur, better
diagnostic accuracy as a result ofthe use of special stains and
the continued specification of new histological sub-types.
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